We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mr
Trivart
Shetty
trivart.shetty@dexcom.com
Dr
Samuel
Seidu
sis11@leicester.ac.uk
Type 2 Diabetes Mellitus
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
People living with type 2 diabetes need to manage their blood sugar levels carefully to reduce the risk of long‑term complications such as heart disease, kidney problems, vision loss, and nerve damage. Many people currently check their blood sugar using finger‑prick tests. Continuous Glucose Monitoring (CGM) systems offer an alternative approach by measuring glucose levels continuously through a small sensor worn on the body.
This study aims to evaluate the use of the Dexcom ONE+ Continuous Glucose Monitoring system in routine primary care settings in the United Kingdom and the Republic of Ireland. The Dexcom ONE+ system is already approved for use in the UK and is CE marked. The study will assess whether using CGM helps improve blood sugar control, increases satisfaction for both participants and healthcare professionals, and can be easily integrated into everyday clinical care without disrupting usual practice.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Diagnosis of type 1 diabetes. 2. Any surgical procedure for weight loss within the year prior to enrolment or plans for undergoing such bariatric surgery during the study. 3. Concomitant disease or condition that in the opinion of the investigator may compromise participant safety, including but not limited to; cystic fibrosis, severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long term medical condition that would interfere with study related tasks or visits. 4. Use of medications known to exacerbate hyperglycaemia (current or for more than 14 days in the past 3 months), corticosteroids (oral and injectable) or certain psychotropics (antipsychotics, e.g., clozapine, olanzapine, risperidone, and quetiapine). 5. Breastfeeding. 6. Anticipated acute uses of glucocorticoids (oral, injectable, or IV), that will affect glycaemic control and impact HbA1c.7. Presence of a haemoglobinopathy or other condition that is expected to affect the measurement of HbA1c in the judgment of the investigator. 8. The participant, immediate family member(s), and/or person(s) living within the household work for Dexcom, Medtronic, Ypsomed, SiBionics, Glysens Inc., Abbott Laboratories, Roche, Senseonics, Waveform, Ascensia Diabetes Care, Yuwell, i-SENS, Bionime, POCTech, or Insulet and any other diabetes company; immediate relation to study staff. 9. Current participation in another interventional study protocol or prior participation in an interventional study protocol in which the participant received active drug within the 90 days prior to screening. Note: Participants will not be excluded if enrolled in another observational trial, wherein the participant is in the follow-up phase and no tests/procedures impacting the participant’s health are required. Participants participating in studies using only approved medications (that are not specifically excluded) or devices may qualify for this study.10. Use of personal real-time or intermittent scanned (Flash) CGM, or use of a glucose biosensor, 6months prior to screening. Note: Previous wear of a professional CGM will not be exclusionary. 11. End stage renal disease currently managed by dialysis or anticipating initiating dialysis during the next 6 months, OR eGFR <15. Note: Baseline blinded CGM data collection can be initiated prior to the lab result being available but lab result must be available prior to initiation to verify eligibility.
Cohort 1 Only 12. Thyroid stimulating hormone (TSH) outside the local laboratory’s reference range (above or below). Note: Baseline blinded CGM data collection can be initiated prior to the lab result being available but lab result must be available to verify eligibility before baseline visit. 13. Known severe allergy to medical grade adhesives or a serious skin condition that precludes use of the CGM. 14. Current or planned use of hydroxyurea.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Dexcom (United States) and funded by Dexcom.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
